Main focus of Oracle's strategy post-Nashville move? | Categorical | | | 8 months ago | |
Oracle to announce more healthcare moves by October 2024? | Binary | | | 8 months ago | |
Oracle stock up 10% post-Nashville move by July 2024? | Binary | | | 8 months ago | |
Oracle to secure major healthcare partnership by April 2025? | Binary | | | 8 months ago | |
First major Oracle initiative post-Nashville move by sector | Categorical | | | 8 months ago | |
Oracle CEO one year post-Nashville move? | Categorical | | | 8 months ago | |
Will Revolution Medicines' RMC-6236 Phase 3 trial start by December 31, 2024? | Binary | | | 5 months ago | |
Will RMC-6236 receive FDA approval by December 31, 2026? | Binary | | | 5 months ago | |
What will be the median PFS in the RMC-6236 Phase 3 trial by December 31, 2025? | Categorical | | | 5 months ago | |
What will be the adverse event rate in the RMC-6236 Phase 3 trial by December 31, 2025? | Categorical | | | 5 months ago | |
Will RMC-6236 achieve its primary endpoint in the Phase 3 trial by December 31, 2025? | Binary | | | 5 months ago | |
How will Revolution Medicines' stock price change within one week after the Phase 3 trial results announcement? | Categorical | | | 5 months ago | |
